NASDAQ:OCGN Ocugen (OCGN) Stock Price, News & Analysis $1.05 +0.01 (+0.96%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.48%) As of 08/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ocugen Stock (NASDAQ:OCGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ocugen alerts:Sign Up Key Stats Today's Range$1.04▼$1.0750-Day Range$0.92▼$1.1752-Week Range$0.52▼$1.33Volume1.20 million shsAverage Volume2.22 million shsMarket Capitalization$306.92 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Read More Ocugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreOCGN MarketRank™: Ocugen scored higher than 30% of companies evaluated by MarketBeat, and ranked 822nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOcugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcugen has only been the subject of 2 research reports in the past 90 days.Read more about Ocugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocugen are expected to decrease in the coming year, from ($0.20) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcugen has a P/B Ratio of 105.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ocugen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.60% of the float of Ocugen has been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Ocugen has recently decreased by 2.44%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.60% of the float of Ocugen has been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Ocugen has recently decreased by 2.44%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.72 News SentimentOcugen has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ocugen this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows9 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.42% of the stock of Ocugen is held by insiders.Percentage Held by InstitutionsOnly 10.27% of the stock of Ocugen is held by institutions.Read more about Ocugen's insider trading history. Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCGN Stock News HeadlinesOcugen IncAugust 25, 2025 | edition.cnn.comOcugen reports EMA positive advice for acceptability of OCU410STAugust 13, 2025 | msn.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt DiseaseAugust 13, 2025 | globenewswire.comOcugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 12, 2025 | globenewswire.comOcugen, Inc. Announces $20 Million Securities Purchase Agreement with Janus Henderson InvestorsAugust 8, 2025 | quiverquant.comQOcugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and WarrantsAugust 8, 2025 | globenewswire.com3OCGN : Demystifying Ocugen: Insights From 5 Analyst ReviewsAugust 4, 2025 | benzinga.comSee More Headlines OCGN Stock Analysis - Frequently Asked Questions How have OCGN shares performed this year? Ocugen's stock was trading at $0.8050 at the beginning of 2025. Since then, OCGN shares have increased by 30.4% and is now trading at $1.05. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings results on Friday, August, 1st. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. The firm earned $1.37 million during the quarter, compared to analyst estimates of $0.35 million. Ocugen had a negative net margin of 1,197.71% and a negative trailing twelve-month return on equity of 255.25%. Read the conference call transcript. Who are Ocugen's major shareholders? Top institutional shareholders of Ocugen include Geode Capital Management LLC (1.19%), Rinkey Investments (0.40%), Brevan Howard Capital Management LP (0.18%) and Y Intercept Hong Kong Ltd (0.12%). Insiders that own company stock include Shankar Musunuri, Junge Zhang, Prabhavathi Fernandes and Ramesh Kumar. View institutional ownership trends. How do I buy shares of Ocugen? Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocugen investors own include Zomedica (ZOM), American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings8/01/2025Today8/29/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCGN CIK1372299 Webocugen.com Phone(484) 328-4701Fax781-547-4452Employees80Year FoundedN/APrice Target and Rating Average Price Target for Ocugen$6.00 High Price Target$7.00 Low Price Target$4.00 Potential Upside/Downside+471.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.05 million Net Margins-1,197.71% Pretax Margin-1,197.71% Return on Equity-255.25% Return on Assets-86.79% Debt Debt-to-Equity Ratio9.18 Current Ratio1.83 Quick Ratio1.83 Sales & Book Value Annual Sales$4.75 million Price / Sales64.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book105.00Miscellaneous Outstanding Shares292,305,000Free Float279,385,000Market Cap$306.92 million OptionableOptionable Beta3.84 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:OCGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.